Will use MaxCyte’s ExPERT platform for siRNA-based cell therapy APN401 targeting solid tumors and secures manufacturing for upcoming trials.

Contract Pharma Staff07.09.20

APEIRON Biologics AG, a private biotechnology company specializing in the discovery, development and commercialization of novel immunotherapies for cancer and respiratory diseases, and MaxCyte, Inc., a global cell-based therapies and life sciences company, have signed a clinical and commercial licensing agreement.

APEIRON Biologics will obtain non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation technology and ExPERT platform to advance APN401, a siRNA-based cell therapy currently in clinical development for various solid tumors. In return, MaxCyte will receive undisclosed development and approval milestones and sales-based payments in addition to other licensing fees.

Source link